Furthermore, CIK therapy plus anti-PD-1 treatment was shown to be a feasible combination therapy method to promote the anti-tumor response of CIK cells and inhibit tumor progression, especially for NSCLC patients with dysfunctional and low proportion of CD4+ T cells in their peripheral blood. This evidence concerns the gene CD4 and neoplasm.